News & Events about Nuvalent Inc.
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 PR Newswire CAMBRIDGE, Mass., Dec. 13, 2022...
Nuvalent Announces Closing of Upsized Public Offering of Common Stock Nuvalent Announces Closing of Upsized Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass., Nov. 3, 2022 CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical...
Nuvalent Announces Pricing of Public Offering of Common Stock Nuvalent Announces Pricing of Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass., Oct. 31, 2022 CAMBRIDGE, Mass., Oct. 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused...
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients...
Thinking about buying stock in Nuvalent, Tesla, Flagstar Bancorp, Mullen Automotive, or GameStop? Thinking about buying stock in Nuvalent, Tesla, Flagstar Bancorp, Mullen Automotive, or GameStop? PR Newswire NEW YORK, Oct. 28, 2022 NEW YORK, Oct. 28, 2022 /PRNewswire/ -- InvestorsObserverissues...